LYT-100 in Healthy Volunteers and BCRL

• ClinicalTrials.gov Identifier: NCT04243837
• Recruitment Status: Completed
• First Posted: January 28, 2020
• Last Update Posted: September 28, 2022
• Sponsor: PureTech
• Collaborator: Novotech (Australia) Pty Limited
• Information provided by (Responsible Party): PureTech

Study Description

Brief Summary:

Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine safety, tolerability, and pharmacokinetic (PK) profile under fed conditions.

Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fed and fasted conditions.

Part 3 is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema

Condition or disease	Intervention/treatment	Phase
Breast Cancer Related Lymphoedema; Lymphoedema	Drug: LYT-100; Other: Matching Placebo; Drug: LYT-100 Food Effect; Drug: LYT-100 BCRL; Drug: Placebo BCRL	Phase 1; Phase 2

Detailed Description:

Part 1: This is a randomised, double-blind, placebo-controlled, multiple ascending dose design to assess the safety, tolerability and PK profile of multiple doses of LYT-100 administered under fed conditions at steady state in healthy participants. Up to 4 dosing cohorts are planned.

Part 2: A dose level below the MTD in Part 1 will be used in Part 2. Subjects will be administered a single dose of their assigned treatment under fasting conditions followed by a wash out period then they will receive a single dose of the same assigned treatment under fed conditions. This will permit a comparison of the PK profile and bioavailability in both fed and fasted states. .

Part 3: Once the optimal dose and regimen is determined with or without food, Part 3 will follow with a randomised, double-blinded, placebo controlled design that will assess the safety, tolerability, and secondarily clinical efficacy of LYT-100 over a period of up to 6-months of dosing in breast carcinoma patients with secondary lymphoedema following sentinel lymph node biopsy and/or axillary node dissection, with or without radiation.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Part 1 consists of 5 cohorts with active treatment or placebo Part 2 consists of 1 cohort with active treatment or placebo Part 3 consists of 1 cohort with active treatment or placebo
• Masking: Triple (Participant, Care Provider, Investigator)

Masking Description

Part 1 and Part 2 are double-blind during the data collection. Determination for dose escalation maybe made under unblinded conditions by assessors.

Part 3 is double-blinded

• Primary Purpose: Treatment
• Official Title: A Phase 1 Multiple Ascending Dose and Food Effect Study in Healthy Volunteers to Determine the Pharmacokinetics and Maximally Tolerated Dose of Deupirfenidone (LYT-100) Followed by a Randomized Double-Blind Placebo-Controlled Phase 2a in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema
• Actual Study Start Date: March 1, 2020
• Actual Primary Completion Date: September 9, 2022
• Actual Study Completion Date: September 9, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: LYT-100 in healthy volunteers with Food; LYT-100, multiple ascending	Drug: LYT-100; LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug. HV subjects will receive multiple ascending doses, starting at 100 mg BID up to 1000 mg, with food for 5-days.; Other Name: Deupirfenidone
Placebo Comparator: Placebo in healthy volunteers with Food; Placebo, multiple administrations	Other: Matching Placebo; Inactive capsule(s)
Experimental: LYT-100 in healthy volunteers, Fasted; LYT-100, Dose below MTD for 1 dose	Drug: LYT-100 Food Effect; LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug. HV subjects will receive one dose of LYT-100 or Placebo; Other Name: Deupirfenidone
Placebo Comparator: Placebo in healthy volunteers, Fasted; Placebo, for 1 administration	Drug: LYT-100 Food Effect; LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug. HV subjects will receive one dose of LYT-100 or Placebo; Other Name: Deupirfenidone
Experimental: LYT-100 in healthy volunteers, Fed; LYT-100, Dose below MTD for 1 dose	Drug: LYT-100 Food Effect; LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug. HV subjects will receive one dose of LYT-100 or Placebo; Other Name: Deupirfenidone
Placebo Comparator: Placebo in healthy volunteers, Fed; Placebo, for 1 administration	Drug: LYT-100 Food Effect; LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug. HV subjects will receive one dose of LYT-100 or Placebo; Other Name: Deupirfenidone
Experimental: LYT-100 in patients with BCRL; LYT-100 BID for 6 months	Drug: LYT-100 BCRL; BCRL patients will receive LYT-100 BID for 6 months; Other Name: Deupirfenidone
Placebo Comparator: Placebo in patients with BCRL; Placebo BID for 6 months	Drug: Placebo BCRL; BCRL patients will receive Placebo BID for 6 months; Other Name: Placebo

Outcome Measures

Primary Outcome Measures :

1. Safety and tolerability: treatment-emergent adverse events (TEAEs) [ Time Frame: 7 days (main time frame) ]
   Evaluate the safety and tolerability of LYT-100 as measured by TEAEs
2. Use pharmacokinetics to characterize the plasma concentration of LYT-100 [ Time Frame: 7 days (main time frame) ]
   Measure observed concentration of LYT-100 in blood plasma

Secondary Outcome Measures :

1. Efficacy signals of LYT-100 [ Time Frame: 6 months ]
   Explore efficacy signals of LYT-100 in breast cancer patients with lymphedema
2. Effect of food on the pharmacokinetic profile of LYT-100 based on plasma concentration of LYT-100 [ Time Frame: 2 days (main time frame) ]
   Measure concentration of LYT-100 in blood plasma in fed or fasted subjects

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Main Inclusion Criteria:

Part 1 and 2: Healthy Volunteers

1. Male or female between 18 and 75 years old (inclusive) at the time of screening.
2. In good general health at screening, free from clinically significant unstable medical, surgical or psychiatric illness, at the discretion of the Investigator.

Part 3: Patients with BRCL

1. Female or male between 18 and 80 years old (inclusive) at the time of informed consent.
2. At least 6 months since any type of breast cancer surgery (excluding fine needle aspiration biopsy [FNA]), at the time of study screening. No intention to have breast reconstructive surgery, nipple reconstruction and/or tattooing during the course of the study.
3. At least 3 months since completion of all types of treatment for breast cancer, including but not limited to neoadjuvant, radiotherapy, chemotherapy and immunotherapy, at the time of study screening.
4. At least 3 months treatment of stable adjuvant treatment with hormonal or anti-HER2 therapy at the time of screening, with no planned changes to this therapy throughout the duration of the study.
5. Diagnosis of primary breast cancer, and without evidence of recurrence of breast cancer and/or metastasis for at least 6 months since breast cancer surgery, as determined at screening and baseline.
6. Documented evidence of Stage 1 or 2 lymphedema.
7. Receiving standard of care compression or agreeable to using care compression, or no compression at all ≥ 4 weeks prior to screening and throughout the study.

Main Exclusion Criteria:

Part 1 and 2: Healthy Volunteers

1. History or presence of malignancy at screening or baseline, with the exception of adequately treated localised skin cancer (basal cell or squamous cell carcinoma) or carcinoma in-situ of the cervix.
2. Clinically significant infection within 28 days of the start of dosing, or infections requiring parenteral antibiotics within the 6 months prior to screening.
3. Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to study drug administration; corticosteroids are permitted at the discretion of the Investigator).
4. History or presence at screening or baseline of a condition associated with significant immunosuppression

Part 3: Patients with BRCL

1. Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e., sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or lymphatic or vascular malformation, determined at screening.
2. Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to study drug administration; corticosteroids are permitted at the discretion of the PI.
3. Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis, dermatitis, necrotizing fasciitis, or current open wounds or sores in the affected extremity.
4. Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema greater than 4 years, determined at screening.
5. Initiated use of compression or manual lymphatic drainage or other lymphoedema therapies at the start of the study within 4 weeks of the screening visit. Rescreening is allowed following a course of stable compression regimen of > 4 weeks.

Contacts and Locations

Locations

United States, California

City of Hope National Medical Center

Duarte, California, United States, 91010

MACRO Trials

Los Angeles, California, United States, 91105

Australia, Queensland

University of the Sunshine Coast

Sippy Downs, Queensland, Australia

Australia, Victoria

Ballarat Health Services

Ballarat, Victoria, Australia

Nucleus Network VIC

Melbourne, Victoria, Australia, 3004

Australia

Flinders University

Adelaide, Australia

Macquarie University Health Sciences Centre

Sydney, Australia

Sponsors and Collaborators

PureTech

Novotech (Australia) Pty Limited

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Chen MC, Korth CC, Harnett MD, Elenko E, Lickliter JD. A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases. Clin Pharmacol Drug Dev. 2022 Feb;11(2):220-234. doi: 10.1002/cpdd.1040. Epub 2021 Nov 15.

• Responsible Party: PureTech
• ClinicalTrials.gov Identifier: NCT04243837
• Other Study ID Numbers: LYT-100-2020-01
• First Posted: January 28, 2020
• Last Update Posted: September 28, 2022
• Last Verified: April 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lymphedema; Breast Cancer Lymphedema; Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Lymphatic Diseases; Postoperative Complications; Pathologic Processes; Pirfenidone; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents